Nonketotic Hyperglycinemia

Nonketotic Hyperglycinemia

Overview

Nonketotic Hyperglycinemia is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is a rare autosomal recessive inborn error of metabolism characterized by impaired glycine cleavage and resulting in toxic accumulation of glycine in the brain and other tissues[@hamosh2002]. The disease typically presents in infancy with catastrophic neurological deterioration, including profound hypotonia, myoclonic seizures, and developmental arrest[@tress2011]. NKH represents one of the most devastating metabolic encephalopathies, with most affected individuals experiencing severe neurodevelopmental disability despite aggressive treatment[@korman2006].

Epidemiology

Nonketotic hyperglycinemia is an extremely rare disorder with an estimated incidence of 1 in 60,000 to 1 in 76,000 live births[@lthy1991]. The disease shows equal distribution between males and females with no ethnic predominance, though founder mutations have been identified in certain isolated populations[@nielsen2019]. The incidence is higher in populations with higher rates of consanguinity due to the autosomal recessive inheritance pattern[@boneh2008]. Approximately 80% of NKH cases present within the neonatal period (classic neonatal form), while the remainder present in infancy or later childhood with milder phenotypes[@carson1992].

Nonketotic Hyperglycinemia

Overview

Nonketotic Hyperglycinemia is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is a rare autosomal recessive inborn error of metabolism characterized by impaired glycine cleavage and resulting in toxic accumulation of glycine in the brain and other tissues[@hamosh2002]. The disease typically presents in infancy with catastrophic neurological deterioration, including profound hypotonia, myoclonic seizures, and developmental arrest[@tress2011]. NKH represents one of the most devastating metabolic encephalopathies, with most affected individuals experiencing severe neurodevelopmental disability despite aggressive treatment[@korman2006].

Epidemiology

Nonketotic hyperglycinemia is an extremely rare disorder with an estimated incidence of 1 in 60,000 to 1 in 76,000 live births[@lthy1991]. The disease shows equal distribution between males and females with no ethnic predominance, though founder mutations have been identified in certain isolated populations[@nielsen2019]. The incidence is higher in populations with higher rates of consanguinity due to the autosomal recessive inheritance pattern[@boneh2008]. Approximately 80% of NKH cases present within the neonatal period (classic neonatal form), while the remainder present in infancy or later childhood with milder phenotypes[@carson1992].

Genetics and Molecular Pathogenesis

Glycine Cleavage System

The glycine cleavage system (GCS) is a mitochondrial enzyme complex responsible for glycine catabolism. It consists of four protein components:

The GCS catalyzes the cleavage of glycine into CO₂, NH₃, and a one-carbon unit transferred to tetrahydrofolate, representing the major pathway for glycine degradation in mitochondria[@sershen1976].

Disease-Causing Mutations

Mutations in any of the four GCS component genes can cause NKH:

| Gene | Protein | OMIM | Proportion of Cases |
|------|---------|------|---------------------|
| GLDC | Glycine decarboxylase | 238300 | ~70-80% |
| GCSH | H-protein | 238330 | ~10-15% |
| AMT | T-protein | 238310 | ~10-15% |
| GLY DLDH | L-protein | 238331 | <5% |

Over 300 disease-causing mutations have been identified, including:

• Missense mutations: Often result in partially functional enzymes
• Nonsense/frameshift mutations: Lead to truncated non-functional proteins
• Splice site mutations: Cause exon skipping
• Large deletions: Less common[@matsuo2020]

Pathophysiology

Glycine Neurotoxicity

Glycine acts as both an inhibitory and excitatory neurotransmitter in the central nervous system:

In NKH, the excessive accumulation of glycine produces a paradoxical effect:

• Overinhibition: Excessive glycine binding to GlyRs in brainstem and spinal cord causes profound hypotonia, apnea, and respiratory failure[@kurki2019]
• [NMDA receptor](/entities/nmda-receptor) overstimulation: Elevated glycine acts as a co-agonist at NMDA receptors, leading to excitotoxic neuronal damage[@mcdonald1990]

Brain Regions Affected

The pattern of brain injury in NKH reflects regional vulnerability to glycine toxicity:

• Brainstem: Respiratory centers, leading to apnea and respiratory failure
• Cerebellum: Purkinje cell loss, contributing to ataxia
• Corpus callosum: Dysmyelination and agenesis
• Cerebral [cortex](/brain-regions/cortex): Cortical dysplasia and neuronal loss[@shalak2005]

Biochemical Abnormalities

• Elevated CSF glycine: Typically 10-30 times normal levels (CSF:plasma ratio >0.08 is diagnostic)
• Elevated plasma glycine: 3-10 times normal
• Absence of ketoacidosis: Distinguishes NKH from ketotic hyperglycinemias
• Elevated urine glycine: Secondary to increased plasma levels[@schiffmann2019]

Clinical Presentation

Classic Neonatal Form (80% of cases)

Presentation occurs within the first days to weeks of life:

• Profound hypotonia: "Floppy infant" appearance
• Lethargy: Progressively obtunded state
• Apnea episodes: Due to brainstem dysfunction
• Myoclonic seizures: Characteristic hiccup-like myoclonus
• Developmental arrest: Failure to achieve milestones
• Severe intellectual disability: In survivors[@von2021]

Infantile Form (15% of cases)

Onset between 1-6 months:

• Seizures: Often the presenting symptom
• Hypotonia: Progressive rather than congenital
• Developmental regression: Loss of previously acquired skills
• Ataxia: Cerebellar involvement
• Myoclonus: Less prominent than neonatal form[@hayasaka1987]

Transient NKH

A rare variant where symptoms improve over time:

• Self-limited course: Symptoms resolve by 2-3 years of age
• Normal development: May achieve normal milestones
• Possible genotype: Often associated with specific mutations[@yoshida1992]

Late-Onset Variants

Very rare presentations in childhood or adulthood:

• Intellectual disability: Variable severity
• Seizures: May be the presenting symptom
• Ataxia: Progressive cerebellar involvement
• Spasticity: Upper motor neuron signs[@bank2019]

Diagnosis

Key Diagnostic Tests

Differential Diagnosis

• Ketotic hyperglycinemia: Associated with propionic acidemia or methylmalonic acidemia
• Hyperglycinuria: Isolated renal glycine wasting without neurological symptoms
• Serine deficiency disorders: Similar neurological phenotype but low serine

Treatment

Pharmacological Approaches

Sodium Benzoate

Sodium benzoate conjugates glycine in the liver, reducing plasma and CSF glycine levels:

• Dose: 250-500 mg/kg/day in 4 divided doses
• Mechanism: Conjugation to hippurate for renal excretion
• Monitoring: Plasma glycine levels, liver function
• Efficacy: May reduce seizures and improve alertness[@matsumoto1982]

Sodium Valproate

Valproic acid should be AVOIDED as it inhibits mitochondrial glycine metabolism and may worsen symptoms[@kure1991].

Benzoate and Dextromethorphan

Combination therapy may provide additional benefit:

• Dexamethorphan: NMDA receptor antagonist
• May reduce excitotoxicity: Theoretical benefit[@crombez1995]

Dietary Management

Glycine Restriction

Very low glycine diet may be beneficial:

• Specialized formulas: Glycine-free medical foods
• Limited efficacy: Difficult to implement in infants
• Nutritional risks: Requires careful monitoring[@michalsmatalon2019]

Supportive Care

• Seizure control: Antiepileptic drugs (avoid valproate)
• Respiratory support: CPAP or mechanical ventilation as needed
• Feeding support: Nasogastric or gastrostomy feeding
• Physical therapy: Maintain joint mobility
• Developmental interventions: Early intervention services[@roth2018]

Prognosis

The prognosis for classic NKH is poor:

• Mortality: 30-50% die in the neonatal period from apnea or complications
• Survivors: Profound intellectual disability in >90%
• Motor skills: Most never achieve ambulation
• Communication: Limited or absent speech in most

Animal Models

Murine Models

Several mouse models recapitulate NKH:

• GLDC knockout mice: Severe phenotype with embryonic or early postnatal lethality
• GCSH-deficient mice: Milder phenotype allowing study of pathogenesis
• Conditional models: Tissue-specific knockouts for mechanistic studies[@obara2019]

Biochemical Studies

Animal models have demonstrated:

• Elevated brain glycine preceding neurological symptoms
• NMDA receptor-mediated excitotoxicity
• Cerebellar Purkinje cell vulnerability
• Potential for therapeutic intervention[@pardo2020]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

Recent research on nonketotic hyperglycinemia has advanced understanding of glycine encephalopathy pathophysiology and potential therapeutic approaches.

References